Literature DB >> 18840028

Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients.

Anisha E Mendonza1, Reginald Y Gohh, Fatemeh Akhlaghi.   

Abstract

BACKGROUND AND OBJECTIVES: Long-term diabetes mellitus may affect the absorption, distribution and metabolism of immunosuppressive agents used after organ transplantation. The aims of this study were to characterize ciclosporin pharmacokinetics in blood and plasma and to compare the ciclosporin unbound concentration and the blood : plasma concentration (B : P) ratio in diabetic kidney transplant recipients. PATIENTS AND METHODS: Ciclosporin 12-hour steady-state pharmacokinetics were studied in eight diabetic and nine nondiabetic patients. Ciclosporin concentrations in whole blood and in plasma were measured using liquid chromatography-tandem mass spectrometry, and the ciclosporin fraction unbound (f(u)) was determined by an equilibrium dialysis method utilizing [(3)H]ciclosporin as a tracer. Oral absorption of paracetamol (acetaminophen) was used as a marker for gastric emptying.
RESULTS: In diabetic patients, the time to the peak blood ciclosporin concentration at steady state (t(max)(,ss)) was prolonged (128 minutes vs 93 minutes in nondiabetic patients, p < 0.01) and, on average, the paracetamol t(max) was prolonged by 30 minutes. The whole-blood dose-normalized area under the concentration-time curve from 0 to 12 hours (AUC(12)) was marginally lower in diabetic patients (p = 0.09) and the plasma AUC(12) was significantly lower (p = 0.03). The ciclosporin f(u) was numerically higher in diabetic patients (1.20 +/- 0.65% vs 0.72 +/- 0.28% in nondiabetic patients, p = 0.066); however, the unbound concentration values were essentially similar in the two groups (0.58 +/- 0.76 microg/L in diabetic patients and 0.52 +/- 0.48 microg/L in nondiabetic patients; p = 0.59). No difference was observed in the ciclosporin B : P ratio between the two groups.
CONCLUSION: This study indicates that diabetes delays ciclosporin absorption, reduces ciclosporin exposure and increases the ciclosporin f(u) but not the pharmacologically active unbound concentration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18840028     DOI: 10.2165/00003088-200847110-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  42 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Cyclosporine trough levels in diabetic and nondiabetic renal transplant patients.

Authors:  S Wadhawan; H Jauhari; S Singh
Journal:  Transplant Proc       Date:  2000-11       Impact factor: 1.066

3.  Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy.

Authors:  Kilian Kelly; Bridget O'Mahony; Blythe Lindsay; Tamara Jones; Tim J Grattan; Amin Rostami-Hodjegan; Howard N E Stevens; Clive G Wilson
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

4.  Cyclosporine toxicity in immunosuppressed streptozotocin-diabetic nonhuman primates.

Authors:  Martin Wijkstrom; Nicole Kirchhof; Melanie Graham; Elizabeth Ingulli; Robert B Colvin; Uwe Christians; Bernhard J Hering; Henk-Jan Schuurman
Journal:  Toxicology       Date:  2005-02-01       Impact factor: 4.221

Review 5.  Cyclosporine drug interactions: a review.

Authors:  N K Wadhwa; T J Schroeder; A J Pesce; S A Myre; C W Clardy; M R First
Journal:  Ther Drug Monit       Date:  1987-12       Impact factor: 3.681

6.  Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry.

Authors:  Anisha E Mendonza; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Ther Drug Monit       Date:  2006-06       Impact factor: 3.681

7.  Long-term diabetes alters the hepatobiliary clearance of acetaminophen, bilirubin and digoxin.

Authors:  J B Watkins; S E Sherman
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

8.  Temperature-dependent binding of cyclosporine to an erythrocyte protein.

Authors:  R P Agarwal; G A Threatte; R A McPherson
Journal:  Clin Chem       Date:  1987-04       Impact factor: 8.327

9.  Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism.

Authors:  N Okabe; N Hashizume
Journal:  Biol Pharm Bull       Date:  1994-01       Impact factor: 2.233

10.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.

Authors:  L Pichard; I Fabre; G Fabre; J Domergue; B Saint Aubert; G Mourad; P Maurel
Journal:  Drug Metab Dispos       Date:  1990 Sep-Oct       Impact factor: 3.922

View more
  5 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  Altered Transport and Metabolism of Phenolic Compounds in Obesity and Diabetes: Implications for Functional Food Development and Assessment.

Authors:  Benjamin W Redan; Kimberly K Buhman; Janet A Novotny; Mario G Ferruzzi
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

3.  Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model.

Authors:  Khalid M Alkharfy
Journal:  Exp Diabetes Res       Date:  2009-10-20

Review 4.  Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.

Authors:  Lucy Darakjian; Malavika Deodhar; Jacques Turgeon; Veronique Michaud
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

Review 5.  Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.

Authors:  Yiting Yang; Xiaodong Liu
Journal:  Pharmaceutics       Date:  2020-04-11       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.